A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)

Current Recommendations for Systemic Therapy of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

(2017) Matthew G. Fury et al.   Journal of the National Comprehensive Cancer Network

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

(2011) C. Kollmannsberger et al.   ANNALS OF ONCOLOGY

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors

(2011) Matthew G. Fury et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer

(2010) Suresh S. Ramalingam et al.   CANCER

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab

(2010) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

(2009) M Campone et al.   BRITISH JOURNAL OF CANCER

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins

(2008) Medhi Wangpaichitr et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

(2008) Chandra P. Belani et al.   JOURNAL OF CLINICAL ONCOLOGY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE